Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations]
Background Chronic migraine is a disabling condition that can substantially impact on quality of life. People with chronic migraine have headaches on at least 15 days of every month. Preventative medications aiming to reduce number of days with migraine are available, but high-quality randomised evi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2025-04-01
|
| Series: | NIHR Open Research |
| Subjects: | |
| Online Access: | https://openresearch.nihr.ac.uk/articles/4-16/v2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849720781718683648 |
|---|---|
| author | Martin Underwood Andrew Cooklin Sophie Rees Manjit Matharu Callum Duncan Hema Mistry Seyran Naghdi |
| author_facet | Martin Underwood Andrew Cooklin Sophie Rees Manjit Matharu Callum Duncan Hema Mistry Seyran Naghdi |
| author_sort | Martin Underwood |
| collection | DOAJ |
| description | Background Chronic migraine is a disabling condition that can substantially impact on quality of life. People with chronic migraine have headaches on at least 15 days of every month. Preventative medications aiming to reduce number of days with migraine are available, but high-quality randomised evidence is lacking for many drugs, and it is unclear which medications should be prioritised for research. There is also no existing evidence about patient and clinicians’ priorities for research. Methods We undertook a consensus workshop with patient and healthcare professional stakeholders, using nominal group technique, to understand these stakeholders’ priorities for future randomised controlled trials. We reached a consensus on a set of research recommendations for the field. Results Eight people with chronic migraine and eleven healthcare professionals took part in an online workshop. Comparisons of calcitonin gene-related peptide monoclonal antibodies (CGRP MAbs) and OnabotulinumtoxinA (BTA) were a top priority for our group. Candesartan and Flunarizine were the top drugs the group wanted to compare against placebo. Conclusions These research recommendations should guide researchers in the field, and funders when prioritising commissioned research and assessing funding applications. Particular areas to explore further are Candesartan or Flunarizine versus placebo, and comparing and combining CGRP MAbs with other medications. |
| format | Article |
| id | doaj-art-ac41b6a9ecf34483b52a1a8024f22281 |
| institution | DOAJ |
| issn | 2633-4402 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | NIHR Open Research |
| spelling | doaj-art-ac41b6a9ecf34483b52a1a8024f222812025-08-20T03:11:52ZengF1000 Research LtdNIHR Open Research2633-44022025-04-01410.3310/nihropenres.13548.214898Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations]Martin Underwood0Andrew Cooklin1Sophie Rees2https://orcid.org/0000-0003-4399-2049Manjit Matharu3Callum Duncan4Hema Mistry5https://orcid.org/0000-0002-5023-1160Seyran Naghdi6https://orcid.org/0000-0001-5504-7189Warwick Clinical Trials Unit, University of Warwick, Coventry, England, CV4 7AL, UKPatient Representative, England, UKBristol Trials Centre, Bristol University, Bristol, BS8 1NU, UKQueen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London, London, England, UKDepartment of Neurology, Aberdeen Royal Infirmary, Aberdeen, Scotland, AB25 2ZN, UKWarwick Clinical Trials Unit, University of Warwick, Coventry, England, CV4 7AL, UKWarwick Clinical Trials Unit, University of Warwick, Coventry, England, CV4 7AL, UKBackground Chronic migraine is a disabling condition that can substantially impact on quality of life. People with chronic migraine have headaches on at least 15 days of every month. Preventative medications aiming to reduce number of days with migraine are available, but high-quality randomised evidence is lacking for many drugs, and it is unclear which medications should be prioritised for research. There is also no existing evidence about patient and clinicians’ priorities for research. Methods We undertook a consensus workshop with patient and healthcare professional stakeholders, using nominal group technique, to understand these stakeholders’ priorities for future randomised controlled trials. We reached a consensus on a set of research recommendations for the field. Results Eight people with chronic migraine and eleven healthcare professionals took part in an online workshop. Comparisons of calcitonin gene-related peptide monoclonal antibodies (CGRP MAbs) and OnabotulinumtoxinA (BTA) were a top priority for our group. Candesartan and Flunarizine were the top drugs the group wanted to compare against placebo. Conclusions These research recommendations should guide researchers in the field, and funders when prioritising commissioned research and assessing funding applications. Particular areas to explore further are Candesartan or Flunarizine versus placebo, and comparing and combining CGRP MAbs with other medications.https://openresearch.nihr.ac.uk/articles/4-16/v2Chronic migraine stakeholder workshop randomised controlled trialseng |
| spellingShingle | Martin Underwood Andrew Cooklin Sophie Rees Manjit Matharu Callum Duncan Hema Mistry Seyran Naghdi Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations] NIHR Open Research Chronic migraine stakeholder workshop randomised controlled trials eng |
| title | Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations] |
| title_full | Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations] |
| title_fullStr | Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations] |
| title_full_unstemmed | Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations] |
| title_short | Research priorities for randomised controlled trials in chronic migraine preventive medication: A stakeholder consensus workshop [version 2; peer review: 1 approved, 2 approved with reservations] |
| title_sort | research priorities for randomised controlled trials in chronic migraine preventive medication a stakeholder consensus workshop version 2 peer review 1 approved 2 approved with reservations |
| topic | Chronic migraine stakeholder workshop randomised controlled trials eng |
| url | https://openresearch.nihr.ac.uk/articles/4-16/v2 |
| work_keys_str_mv | AT martinunderwood researchprioritiesforrandomisedcontrolledtrialsinchronicmigrainepreventivemedicationastakeholderconsensusworkshopversion2peerreview1approved2approvedwithreservations AT andrewcooklin researchprioritiesforrandomisedcontrolledtrialsinchronicmigrainepreventivemedicationastakeholderconsensusworkshopversion2peerreview1approved2approvedwithreservations AT sophierees researchprioritiesforrandomisedcontrolledtrialsinchronicmigrainepreventivemedicationastakeholderconsensusworkshopversion2peerreview1approved2approvedwithreservations AT manjitmatharu researchprioritiesforrandomisedcontrolledtrialsinchronicmigrainepreventivemedicationastakeholderconsensusworkshopversion2peerreview1approved2approvedwithreservations AT callumduncan researchprioritiesforrandomisedcontrolledtrialsinchronicmigrainepreventivemedicationastakeholderconsensusworkshopversion2peerreview1approved2approvedwithreservations AT hemamistry researchprioritiesforrandomisedcontrolledtrialsinchronicmigrainepreventivemedicationastakeholderconsensusworkshopversion2peerreview1approved2approvedwithreservations AT seyrannaghdi researchprioritiesforrandomisedcontrolledtrialsinchronicmigrainepreventivemedicationastakeholderconsensusworkshopversion2peerreview1approved2approvedwithreservations |